AstraZeneca Moves Toward the Oral GLP-1 Market with Elecoglipron

Jennifer Hardy
7 hours ago
4 min read

The race to develop effective oral GLP-1 medications for obesity is heating up, and AstraZeneca is officially making its move. If you're like me, that means you're also seeing hope that the out-of-pocket costs of these medications, which include Ozempic, Zepbound, and Wegovy, will go down in the future as more players enter the field.

At the 2026 American Diabetes Association Scientific Sessions, AstraZeneca announced positive Phase 2b results for elecoglipron. The medication is an investigational once-daily oral GLP-1 receptor agonist designed to help people lose weight and improve blood sugar control.

The company says the results were strong enough to launch an extensive Phase 3 development program that will include obesity, type 2 diabetes, cardiovascular outcomes, and kidney disease studies.

If approved, elecoglipron could become the third major oral GLP-1 option targeting obesity, joining Novo Nordisk's oral semaglutide (often referred to as Oral Wegovy) and Eli Lilly's investigational orforglipron, which recently received the brand name Foundayo.

What Is Elecoglipron?

Elecoglipron is a small-molecule GLP-1 receptor agonist taken as a daily pill. Unlike peptide-based medications such as semaglutide, it does not require special fasting instructions or food restrictions, which could make it easier for some patients to use consistently.

GLP-1 medications work by mimicking the naturally occurring glucagon-like peptide-1 hormone. They help regulate appetite, slow gastric emptying, increase feelings of fullness, and improve blood sugar control.

"The progression of elecoglipron is an important step in delivering a differentiated weight management portfolio, offering monotherapies and combinations, designed to address the biological complexity of obesity and comorbidities that can be tailored to individual needs, enabling people to live healthier lives." — Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca

Weight Loss Results

In AstraZeneca's VISTA Phase 2b trial, adults living with obesity or overweight plus at least one weight-related condition lost an average of 10.5% of their body weight after 26 weeks on the highest dose of elecoglipron.

The results continued improving through the study's 36-week mark, where participants achieved an average weight loss of 11.8%. Researchers noted that weight loss had not yet plateaued by the end of the trial.

Nearly 89% of participants receiving the highest dose achieved at least 5% weight loss, compared to just 15.6% of those taking a placebo.

The medication also showed improvements in blood pressure and markers of systemic inflammation, suggesting benefits beyond the number on the scale.

Blood Sugar Results in Type 2 Diabetes

In the SOLSTICE Phase 2b trial, adults with type 2 diabetes experienced significant improvements in glucose control. Participants taking the highest dose saw HbA1c levels decrease by 1.9 percentage points over 26 weeks, compared to 0.2 points with placebo.

Additionally:

90% achieved an HbA1c below 7%
85% reached an HbA1c of 6.5% or lower
Average body weight decreased by 7.7%

Researchers reported that gastrointestinal side effects were the most common adverse events, including nausea, constipation, diarrhea, and vomiting, which mirrors the broader GLP-1 medication class.

AstraZeneca's GLP-1 History

While AstraZeneca is often associated with diabetes and cardiovascular medications, this is not the company's first GLP-1 rodeo. The company previously marketed the injectable GLP-1 medications Bydureon and Byetta after acquiring them through its purchase of Bristol-Myers Squibb's diabetes business in 2014.

Byetta (exenatide twice daily) was one of the earliest GLP-1 receptor agonists available in the United States, while Bydureon offered a once-weekly version of the same active ingredient.

For a time, Bydureon helped pave the way for today's GLP-1 market. However, as newer medications like Ozempic and Trulicity demonstrated greater efficacy and easier administration, exenatide-based therapies gradually lost market share.

AstraZeneca discontinued Bydureon BCise in 2024. The decision was not driven by safety concerns but rather by changing market dynamics and the availability of newer GLP-1 therapies that delivered greater weight loss and blood sugar improvements.

Now, the company appears determined to re-enter the GLP-1 spotlight with a product designed specifically for the modern obesity treatment landscape.

How Elecoglipron Compares to Other Oral GLP-1s

If approved, elecoglipron would enter a rapidly evolving oral GLP-1 category that currently has two major contenders.

Foundayo (Orforglipron)

Developed by Eli Lilly, Foundayo is an oral, non-peptide GLP-1 receptor agonist that has generated considerable excitement because it offers weight loss approaching that seen with injectable medications while avoiding injections altogether.

Like elecoglipron, it does not require fasting before dosing, which could improve convenience for patients. Lilly has reported weight loss approaching the mid-teen percentages in late-stage obesity trials, positioning Foundayo as a potential competitor to injectable GLP-1 therapies.

Oral Wegovy

Novo Nordisk's Oral Wegovy beat Eli Lilly's Foundayo to FDA approval. The once-daily semaglutide tablet surpassed three million prescriptions in just over five months after launching in January 2026. That's one of the strongest pharmaceutical launches by prescription volume in U.S. history. For perspective, that works out to a new prescription being filled every five seconds.

Novo Nordisk says more than 80% of those prescriptions came from people who were new to GLP-1 therapy, suggesting the pill is expanding the obesity treatment market rather than simply pulling patients away from injections.

Unlike small-molecule pills such as elecoglipron and Foundayo, Oral Wegovy still requires fasting instructions because it uses semaglutide, the same active ingredient found in injectable Wegovy.

Why Oral GLP-1s Matter

The demand for obesity treatment continues to grow worldwide, but not everyone is comfortable with injections. Some people delay treatment because of needle anxiety. Others travel frequently or simply prefer the convenience of a daily pill.

Oral GLP-1 medications may help expand access by giving patients another option while potentially simplifying manufacturing and distribution compared to injectable peptide-based therapies. Plus, while I'm not a pharmaceutical mathematician, making oral meds has to be cheaper than vials, injectable pens, fluids, and climate control for transporting injection-based GLP-1s.

What Happens Next?

For now, elecoglipron remains investigational. AstraZeneca plans to move elecoglipron into an extensive Phase 3 clinical program that will evaluate the medication in people with obesity, overweight, and type 2 diabetes.

At best, it would be about two years until it hits the market. That's if all goes well. By then, we could also have a GLP-1 landscape that includes the triple-agonist injection retatrutide.

But with Foundayo and Oral Wegovy also advancing through development, the future of obesity treatment may include something many patients have been asking for since the first GLP-1 medications arrived: effective weight-loss pills that don't require a needle.